Successes and failures of current treatment of heart failure

Lancet

Volumn 352, Issue SUPPL.1, 1998, Pages 19-28

  Cleland, John G F ^a,d   Swedberg, Karl ^b   Poole Wilson, Philip A ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; LISINOPRIL; LOSARTAN; METOPROLOL; NITRATE; RAMIPRIL; TIMOLOL; TRANDOLAPRIL;

DRUG EFFICACY; ECHOCARDIOGRAPHY; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROKE; SUDDEN DEATH; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0031686180     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90015-0     Document Type: Article

References (119)

1. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effects of ACE inhibitors on exercise capacity. Eur Heart J 1996; 17: 120-34.
2. Remme WJ, Cleland JGF, et al. European Society of Cardiology: guidelines for the management of heart failure. Eur Heart J 1997; 18: 736-53.
3. Cleland JGF, Erdmann E, Ferrari R, et al. Guidelines for the diagnosis of heart failure. Eur Heart J 1995; 16: 741-51.
4. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in the Framingham heart study subjects. Circulation 1993; 88: 107-15.
5. Cowie MR, Suresh V, Wood DA, et al. Prognosis of heart failure - a population based study of the outcome in incident cases. JACC 1998; 31: 218A (abstr).
6. Brown A, Cleland JGF. Influence of pattern of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998; 19: 1063-69.
7. Reitsma JB, Mosterd A, De Craen AJM, et al. Increase in hospital admission rates for heart failure in the Netherlands, 1980-1993. Heart 1996; 76: 388-92.
8. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
9. Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalisation for heart failure. J Am Geriatrics Society 1997; 45: 270-75.
10. McMurray JM, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14: 1158-62.
11. Cleland JGF. Health economic and quality of life issues in heart failure. Eur Heart J 1998; in press.
12. Cleland JGF. Screening for left ventricular dyfunction and heart failure: should it be done and if so how? Dis Management Health Outcomes 1997; 1: 169-84.
13. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-33.
14. Clark A, Coats AJS. Severity of heart failure and dosages of angiotensin converting enzyme inhibitors. BMJ 1996; 310: 973-74.
15. Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and mangement of heart failure in general practice. Br J Gen Pract 1996; 46: 77-79.
16. Philbin EF, Andreou C, Rocco TA, Lynch LH, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996; 77: 832-38.
17. Hillis GS, Al-Mohammad A, Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996; 76: 427-29.
18. Kjekshus J, Pedersen TR, Olsson AG, Faegeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary disease. J Cardiac Failure 1997; 3: 249-54.
19. European Heart Failure Training Group. Experience from controlled trials of physical training in chronic heart failure: protocol and patient factors in effectiveness in the improvement of exercise tolerance. Eur Heart J 1998; 19: 466-75.
20. Parameshwar J, Shackell MM, Richardson A, Poole Wilson PA, Sutton GC. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract 1992; 42: 287-89.
21. Pitt B, Segal R, Martinez FA, et al on behalf of the ELITE study group. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747-52.
22. Swedberg K, for the CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Lancet 1997; 349: 747-52.
23. The NETWORK Investigators: clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J 1998; 19: 481-89.
24. Cleland JGF. ACE inhibitors for the prevention and treatment of heart failure: why are they 'under used'? J Hum Hypertens 1995; 9: 435-42.
25. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-74.
26. Sherman LG, Chang Seng Liang, Baumgardner S, et al. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-74.
27. Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy 1994; 14: 514-21.
28. Cleland JGF, Cowburn PJ, McMurray JJV. In: Cleland JGF, ed. Heart failure: a systematic guide to clinical practice. London: Science Press, 1997.
29. Walma EP, Hoes AW, Van Dooren C, Prins A, Van der Does E. Withdrawal of long term diuretic medication in elderly patients: a double blind randomisation trial. BMJ 1997; 315: 464-68.
30. Andrews R, Charlesworth A, Evans A, Cowley AJ. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Eur Heart J 1997; 18: 852-57.
31. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic diated cardiomyopathy. Am J Cardiol 1994; 73: 881-86.
32. Richardson A, Scriven AJ, Poole Wilson PA, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987; 2: 709-11.
33. Magnani B, Magelli C. Captopril in mild heart feature: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. Postgrad Med J 1986; 62: 153-58.
34. Lewis SJ, Roberts CJC. Double-blind comparison of high-dose bumetanide and half-dose bumetanide together with captopril in heart failure. Curr Ther Res Clin Exp 1991; 50: 3-13.
35. Cowley AJ, Stainer K, Wynne RD, et al. Symptomatic assessment of patinets with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986; ii: 770-72.
36. Remme WJ, Bodin F, Benazepril heart failure study group. Is monotherapy with ACE inhibition preferable to diuretics in mild heart failure? A comparison of benazepril and hydrochlorothiazide. J Am Coll Cardiol 1996; 27 (suppl A): 228a (abstr).
37. Murray MD, Adams LD, Forthofer MM, et al. Decreased hospitalisation for CHF by using a completely and predictably absorbed loop diuretic. J Am Coll Cardiol 1998; 31 (suppl C): 465C (abstr).
38. Good JM, Peters M, Wilkins M, Jackson N, Oakley CM, Cleland JGF. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol 1995; 25: 1273-81.
39. Abraham WT, Oren RM, Crisman TS, et al. Effects of an oral, nonpeptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure. J Am Coll Cardiol 1997; 29 (suppl): 169A (abstr).
40. Uretsky BF, Young JB, Shahidi E, Yellen LG, Harrison MC, Jolly K, on behalf of the PROVED investigator group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-62.
41. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of dixogin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.
42. The Digitalis Investigation Group: the effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
43. Gheorghiade M, Young JB, Uretsky BF, Packer M. The effects of digoxin withdrawal in patients with stable heart failure due to coronary artery disease compared to primary cardiomyopathy; insights from the PROVED and RADIANCE studies. Circulation 1995; 92: I-142 (abstr).
44. Slatton ML, Irani WN, Hall SA, et al. Does digoxin provide additional hemodynamic and autonomie benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Cell Cardiol 1997; 29: 1206-13.
45. Eriksson SV, Kjekshus J, Offstad J, Swedberg K. Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. Cardiology 1994; 85: 137-44.
46. Carson P, Johnson G, Fletcher R, Cohn J, for the V-HeFT Cooperative Study Group. Mild systolic dysfunction in heart failure (left venticular ejection fraction (>35%): baseline characteristics, prognosis and response to therapy in the vasodilator in heart failure trials (V-HeFT). J Am Coll Cardiol 1996; 27: 642-49.
47. Yusuf S, Nicklas JM, Timmis G, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
48. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dusfunction after myocardial infarction - results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
49. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
50. Ball SG, Hall AS, Mackintosh AF, et al. Effect of ramipril and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28.
51. Kober L, Torp Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-76.
52. Cohn J, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547-52.
53. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatmentof chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
54. Fowler MB, Vagelos RH, Schroeder JS, et al. Comparison of high versus low-dose enalapril therapy on clinical outcomes and neuroendocrine activation in advanced heart failure. Circulation 1997; 96: 1-20 (abstr).
55. Pacer R, Stanek B, Globits S, et al. Effect of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J 1996; 17: 1223-32.
56. Van Veldhuisen DJ, Genth-Zoth S, Netzer T, Brouwer J. High versus low-dose ACE inhibition in patients with chronic heart failure: a placebo controlled study with imidapril. Circulation 1997; 96:1-20 (abstr).
57. Masaki H, Kurihara T, Yamaki A, et al. Cardiac specific ocerexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 1998; 101: 527-35.
58. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-97.
59. Klinger G, Jaramillo N, Ikram H, et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. JACC 1997; 29: 205A (abstr).
60. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-45.
61. Lang RM, Elkayam U, Yellen LG, et al on behalf of the Losartan Pilot Exercise Study Investigators: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. JACC 1997; 30: 983-91.
62. Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomised Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Can J Cardiol 1997; 13: 1166-74.
63. Giles TD, Katz R, Sullivan JM, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989; 13: 1240-47.
64. Pouleur H, Rousseau MF, Oakley C, Ryden L. Difference in mortality between patients treated with captopril or enalapril in the xamoterol in severe heart failure study. Am J Cardiol 1991; 68: 71-74.
65. Epstein SE, Braunwald E. The effect of beta-adrenergic blockade on patients of urinary sodium excretion. Ann Intern Med 1966; 65: 20-27.
66. Snow PJD. Effect of propranolol in myocardial infarction. Lancet 1965; ii: 551-53.
67. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Res 1985; 27: 335-71.
68. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-10.
69. Herlitz J, Hjalmarson A, Holmberg S, et al. Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. Br Heart J 1984; 51: 539-44.
70. Herlitz J. Effect of metoprolol among patients with suspected acute myocardial infarction and left ventricular dysfunction. Eur Heart J 1996; 17 (suppl): 514 (abstr).
71. Gundersen T. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction. Br Heart J 1983; 50: 135-39.
72. Waagstein F, F Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta adrenergic receptor blockade in congestie cardiomyopathy. Br Heart J 1975; 37: 1022-26.
73. Swedberg K, Hjalmarson A, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; i: 1364-66.
74. Cleland JGF, Bristow M, Erdmann E, Remme WJ, Swedberg K, Waggstein F. Beta-blocking agents in heart failure: should they be used and how? Eur Heart J 1996; 17: 1629-39.
75. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-46.
76. Packer M, Bristow MR, Cohn JN, et al, for the US carvedilol study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
77. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure - systematic overview of randomised controlled trials. Eur Heart J 1997; 18: 560-65.
78. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomised trials. J Am Coll Cardiol 1997; 30: 27-34.
79. The CIBIS II Scientific Committee. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). Fundam Clin Pharmacol 1997; 11: 138-42.
80. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
81. Lechat P, Jaillon P, Fontaine ML, et al. A randomized trial of beta-blockade in heart failure: The Cardiac Insuffiiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
82. Parameshwar J, Poole Wilson PA. The role of calcium antagonists in the treatment of chronic heart failure. Eur Heart J 1993; 14: 38-44.
83. Schofer J, Hobuss M, Aschenberg W, Tews A. Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. Eur Heart J 1990; 11: 712-21.
84. Rousseau MF, Melin J, Benedict CR, et al. Effects of nisolidipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994; 15: 957-64.
85. Cohn JN, Ziesche S, Smith R, et al for the Vasodilator-Heart Failure Trial (V-Heft) study group: effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation 1997; 96: 856-63.
86. Packer M, O'Connor CM, Ghali JK, et al for the PRAISE Study Group: effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14.
87. Poole-Wilson PA. Amlodipine in chronic heart failure. N Engl J Med 1997; 336: 1023-24.
88. Brookes CIO, Hart P, Koegh BE, Cleland JGF. Angiography and the aetiology of heart failure. Postgrad Med J 1995; 71: 480-82.
89. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). Am J Cardiol 1992; 69: 1458-66.
90. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997; 79: 738-41.
91. Figuella HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the diltiazem in dilated cardiomyopathy trial. Circulation 1996; 94: 346-52.
92. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: 981-86.
93. Hosenpud JD, Bennet LE, Keck BM, Fiol B, Novick RJ. The registry of the international society for heart and lung transplantation: fourteenth official report - 1997. J Heart Lung Transpl 1998; 16: 691-712.
94. Loebe M, Hennig E, Muller J, Spiegelsberger S, Weng Y, Hetzer R. Long-term mechanical circulatory support as a bridge to transplantation, for recovery from cardiomyopathy, and for permanent replacement. Eur J Cardio Thorac Surg 1997; 11: S18-S24.
95. Loebe M, Weng Y, Muller J, et al. Successful mechanical circulatory support for more than two years with a left ventricular exist device in a patient with dilated cardiomyopathy. J Heart Lung Transplant 1997; 16: 1176-79.
96. Langenburg SE, Buchanan SA, Blackbourne LH, et al. Predicting survival after coronary revascularisation for ischemic cardiomyopathy. Ann Thorac Surg 1995; 60: 1193-97.
97. Louie HW, Laks H, Milgalter E, et al. Ischemic cardiomyopathy - criteria for coronary vascularisation and cardiac transplantation. Circulation 1991; 84: III-290-III-295.
98. Christakis GT, Weisel RD, Frames SE, et al. Coronary artery bypass grafting in patients with poor ventricular function. J Thorac Cardiovasc Surg 1992; 103: 1083-92.
99. Narang R, Cleland JGF, Erhardt L, et al. Mode of death in chronic heart failure: a request for more accurate classification. Eur Heart J 1996; 17: 1390-403.
100. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventriciular arrhythmia. N Engl J Med 1996; 335: 1933-40.
101. The antiarrhythmics versus implantable defibrillators (AVID) investigators: a comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhyhthmias. N Engl J Med 1997; 337: 1576-83.
102. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch trial investigators: Prophylactic use of implanted cardiac defibrillators in patinets at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337: 1569-75.
103. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation following acute myocardial infarction. Circulation 1997; 96:1-75 (abstr).
104. Deedwania PC, Singh BN, Fletcher R, Fisher S, Singh S. Amiodarone improves survival by restoring and maintaining sinus rhythm in patients with chronic atrial fibrillation, dialted cardiomyopathy, and congestie heart failure. Circulation 1996; 94 (suppl): I-663 (abstr).
105. Torp Pedersen C. Dofetilde: a new case III anti-arrhythmic drug which is safe in patients with congestive heart failure. J Am Coll Cardiol 1998; 31 (suppl): 160A (abstr).
106. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opinion Cardiol 1997; 12: 276-87.
107. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-57.
108. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1074-80.
109. Cleland JGF, Swedberg K. Influence of aetiology on the effects of treatment in heart failure. J of Cardiovasc Risk 1998; (in press).
110. Cleland JGF, Puri S. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death? Br Heart J 1994; 72: S81-86.
111. Cleland JGF. ACE inhibitors for myocardial infarction: How should they be used? Eur Heart J 1995; 16: 153-59.
112. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorola K. The effects of simvastatin on the incidence of heart failure patients with coronary heart disease. J Card Fail 1997; 3: 249-54.
113. Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol 1992; 69: 103-07.
114. Rogers WJ, Johnstone DE, Jusuf S, et al. Quality of life among 5025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction. J Am Coll Cardiol 1994; 23: 393-400.
115. Bristow MR, Gilbert EM, Abraham WT, et al. for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-17.
116. Colucci WS, Packer M, Bristow MR, et al. for the US Carvedilol Heart Failure Study Group: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-06.
117. Packer M, Colucci WS, Sackner Bernstein JD, et al. for the PRECISE study group: Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2794-99.
118. Wiklund I, Waagstein F, Swedberg K, Hjalmarson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Cardiovasc Drugs Ther 1996; 10: 361-68.
119. Bulpitt CJ, Fletcher AE. Measurement of the quality of life in congestive heart falure - influence of drug therapy. Cardiovasc Drugs Ther 1988; 2: 419-24.